Reference Limits for Chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and Carcinoembryonic Antigen in Patients with Chronic Kidney Disease. Issue 4 (October 2017)

• Record Type: Journal Article
• Authors: Mikkelsen, Gustav; Åsberg, Arne; Hultström, Maria E.; Aasarød, Knut; Hov, Gunhild G.
• Is Part Of: International journal of biological markers. Volume 32:Issue 4(2017)
• Page Start: 461
• Page End: 466
• Publication Date: 2017-10
• Subjects: Chronic renal insufficiency -- Glomerular filtration rates -- Reference range -- Tumor biomarkers; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.5301/ijbm.5000278
• Languages: English
• ISSNs: 0393-6155

Abstract

Background: Patients with chronic kidney disease (CKD) may have increased plasma concentrations of some tumor markers even when no cancer is present. Previous studies have indicated that plasma concentrations of chromogranin A (CGA), cytokeratin 19 fragments (CYFRA 21-1), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in healthy individuals, and this can make interpretation of results more complicated. The aim of this study was to establish reference limits for these markers in patients with CKD not receiving dialysis and with no clinical evidence of cancer. Methods: We measured plasma concentrations in samples from 131 patients with CKD due to various etiologies and studied the association of tumor marker concentrations with estimated glomerular filtration rate (GFR) and other patient characteristics. Results: Estimated reference limits for plasma CA 125, CA 19-9 and CEA were approximately the same as for healthy populations. Serum concentrations of CGA and CYFRA 21-1 correlated strongly with estimated GFR, and GFR-dependent reference limits were estimated. Conclusions: GFR-dependent reference limits for CGA and CYFRA 21-1 are reported in order to support interpretation of these markers in patients with CKD.